Aptevo Therapeutics Statistics
Share Statistics
Aptevo Therapeutics has 1.46M shares outstanding. The number of shares has increased by 116.57% in one year.
| Shares Outstanding | 1.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -84.52% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.46M |
| Failed to Deliver (FTD) Shares | 191.03K |
| FTD / Avg. Volume | 55.16% |
Short Selling Information
The latest short interest is 241.68K, so 16.57% of the outstanding shares have been sold short.
| Short Interest | 241.68K |
| Short % of Shares Out | 16.57% |
| Short % of Float | 16.58% |
| Short Ratio (days to cover) | 0.59 |
Valuation Ratios
The PE ratio is -4.71 and the forward PE ratio is -0.05.
| PE Ratio | -4.71 |
| Forward PE | -0.05 |
| PS Ratio | 0 |
| Forward PS | 0.9 |
| PB Ratio | 6.7 |
| P/FCF Ratio | -6.99 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aptevo Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.
| Current Ratio | 2.64 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.42% and return on capital (ROIC) is -163.91%.
| Return on Equity (ROE) | -1.42% |
| Return on Assets (ROA) | -0.7% |
| Return on Capital (ROIC) | -163.91% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -435.27K |
| Employee Count | 40 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -98.07% in the last 52 weeks. The beta is 5.07, so Aptevo Therapeutics 's price volatility has been higher than the market average.
| Beta | 5.07 |
| 52-Week Price Change | -98.07% |
| 50-Day Moving Average | 7.73 |
| 200-Day Moving Average | 20.77 |
| Relative Strength Index (RSI) | 38.94 |
| Average Volume (20 Days) | 346.35K |
Income Statement
| Revenue | n/a |
| Gross Profit | -567.00K |
| Operating Income | -28.88M |
| Net Income | -17.41M |
| EBITDA | -28.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -62.62 |
Balance Sheet
The company has 16.90M in cash and 5.40M in debt, giving a net cash position of 11.51M.
| Cash & Cash Equivalents | 16.90M |
| Total Debt | 5.40M |
| Net Cash | 11.51M |
| Retained Earnings | -223.45M |
| Total Assets | 15.15M |
| Working Capital | 4.13M |
Cash Flow
In the last 12 months, operating cash flow was -11.73M and capital expenditures 0, giving a free cash flow of -11.73M.
| Operating Cash Flow | -11.73M |
| Capital Expenditures | 0 |
| Free Cash Flow | -11.73M |
| FCF Per Share | -42.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
APVO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1373.25% |
| FCF Yield | -176.38% |
Analyst Forecast
The average price target for APVO is $296, which is 6391.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $296 |
| Price Target Difference | 6391.2% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 4, 2024. It was a backward split with a ratio of 1:37.
| Last Split Date | Dec 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:37 |
Scores
| Altman Z-Score | -26.9 |
| Piotroski F-Score | 3 |